FibroBiologics, Inc.
FBLG
$0.8762
$0.00120.14%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.23M | 8.59M | 7.93M | 7.22M | 6.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.74M | 12.51M | 11.21M | 10.08M | 8.89M |
| Operating Income | -13.74M | -12.51M | -11.21M | -10.08M | -8.89M |
| Income Before Tax | -11.16M | -17.78M | -19.47M | -22.53M | -16.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.16 | -17.78 | -19.47 | -22.53 | -16.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.16M | -17.78M | -19.47M | -22.53M | -16.49M |
| EBIT | -13.74M | -12.51M | -11.21M | -10.08M | -8.89M |
| EBITDA | -13.58M | -12.37M | -11.09M | -9.99M | -8.84M |
| EPS Basic | -0.35 | -0.60 | -0.67 | -0.77 | -0.68 |
| Normalized Basic EPS | -0.22 | -0.38 | -0.42 | -0.48 | -0.37 |
| EPS Diluted | -0.35 | -0.60 | -0.67 | -0.77 | -0.68 |
| Normalized Diluted EPS | -0.22 | -0.38 | -0.42 | -0.48 | -0.37 |
| Average Basic Shares Outstanding | 131.50M | 125.60M | 120.31M | 115.83M | 112.92M |
| Average Diluted Shares Outstanding | 131.50M | 125.60M | 120.31M | 115.83M | 112.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
